ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which has completed Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists; and the development of peptides as glucagon antagonists to treat type I and type II diabetes; and a clinical development collaboration agreement with Incanthera Limited for Nucant cancer programme. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-20-71524080
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales£137,350.00
Profitability
Miscellaneous
Employees10
Next Earnings Date5/30/2019 (Estimated)
OptionableNot Optionable
ImmuPharma (LON:IMM) Frequently Asked Questions
What is ImmuPharma's stock symbol?
ImmuPharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM."
When is ImmuPharma's next earnings date?
Has ImmuPharma been receiving favorable news coverage?
News articles about IMM stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ImmuPharma earned a coverage optimism score of 1.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future.
Who are some of ImmuPharma's key competitors?
Some companies that are related to ImmuPharma include Actinium Pharmaceuticals (ATNM), Ampio Pharmaceuticals (AMPE), Noxopharm (NOX), Helix Biopharma (HBP), Asterias Biotherapeutics (AST), Biotron (BIT), Immunoprecise Antibodies (IPA), Silence Therapeutics (SLN), AquaBounty Technologies (AQB), Oncolytics Biotech (ONC), Novoheart (NVH), Midatech Pharma (MTPH), Aerpio Pharmaceuticals (ARPO), Sirona Biochem (SBM) and DiaMedica Therapeutics (DMA).
What other stocks do shareholders of ImmuPharma own?
Who are ImmuPharma's key executives?
ImmuPharma's management team includes the folowing people:
- Mr. Dimitri F. Dimitriou, Co-Founder, CEO & Director (Age 57)
- Dr. D. Robert Henri Zimmer M.D., Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 71)
- Ms. Tracy Weimar BA, MBA, VP of Operations & Fin. and Company Sec.
- Dr. Jean-Marie Geiger PharmD, MD, Head of Clinical Devel.
How do I buy shares of ImmuPharma?
Shares of IMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is ImmuPharma's stock price today?
One share of IMM stock can currently be purchased for approximately GBX 10.22.
How big of a company is ImmuPharma?
ImmuPharma has a market capitalization of £14.25 million and generates £137,350.00 in revenue each year. ImmuPharma employs 10 workers across the globe.
What is ImmuPharma's official website?
How can I contact ImmuPharma?
ImmuPharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The company can be reached via phone at +44-20-71524080.
MarketBeat Community Rating for ImmuPharma (LON IMM)
MarketBeat's community ratings are surveys of what our community members think about ImmuPharma and other stocks. Vote "Outperform" if you believe IMM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMM will underperform the S&P 500 over the long term. You may vote once every thirty days.
